Chronic cholestatic liver diseases such as primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) are frequently associated with damage to the barrier function of the biliary epithelium, but barrier function is difficult to study in vivo and has not been recapitulated in vitro. Here we report the development of a bile duct-on-a-chip that phenocopies not only the tubular architecture of the bile duct in three dimensions, but also its barrier functions. We demonstrated that mouse cholangiocytes in the channel of the device became polarized and formed mature tight junctions, and that the permeability of the cholangiocyte monolayer was comparable to that measured ex vivo for the rat bile duct. Permeability decreased significantly when cells formed a compacted monolayer with cell densities comparable to that seen in vivo. This device enabled independent access to the apical and basolateral surfaces of the cholangiocyte channel, allowing proof-of-concept toxicity studies with the biliary toxin biliatresone and the bile acid glycochenodeoxycholic acid. The cholangiocyte basolateral side was more vulnerable than the apical side to treatment with either agent, suggesting a protective adaptation of the apical surface that is normally exposed to bile. Further studies revealed a protective role of the cholangiocyte apical glycocalyx, wherein disruption of the glycocalyx with neuraminidase increased the permeability of the cholangiocyte monolayer after treatment with glycochenodeoxycholic acid. Conclusion: This bile ducton-a-chip captured essential features of a simplified bile duct in structure and organlevel functions and represents a novel in vitro platform to study the pathophysiology of the bile duct using cholangiocytes from a variety of sources. 
Abstract
Chronic cholestatic liver diseases such as primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) are frequently associated with damage to the barrier function of the biliary epithelium, but barrier function is difficult to study in vivo and has not been recapitulated in vitro. Here we report the development of a bile duct-on-a-chip that phenocopies not only the tubular architecture of the bile duct in three dimensions, but also its barrier functions. We demonstrated that mouse cholangiocytes in the channel of the device became polarized and formed mature tight junctions, and that the permeability of the cholangiocyte monolayer was comparable to that measured ex vivo for the rat bile duct. Permeability decreased significantly when cells formed a compacted monolayer with cell densities comparable to that seen in vivo. This device enabled independent access to the apical and basolateral surfaces of the cholangiocyte channel, allowing proof-of-concept toxicity studies with the biliary toxin biliatresone and the bile acid glycochenodeoxycholic acid. The cholangiocyte basolateral side was more vulnerable than the apical side to treatment with either agent, suggesting a protective adaptation of the apical surface that is normally exposed to bile. Further studies revealed a protective role of the cholangiocyte apical glycocalyx, wherein disruption of the glycocalyx with neuraminidase increased the permeability of the cholangiocyte monolayer after treatment with glycochenodeoxycholic acid. Conclusion: This bile ducton-a-chip captured essential features of a simplified bile duct in structure and organlevel functions and represents a novel in vitro platform to study the pathophysiology of the bile duct using cholangiocytes from a variety of sources.
Introduction
Chronic cholestatic liver diseases such as primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) are often associated with alterations in the tight junctions of bile duct epithelial cells (cholangiocytes). Data from mouse models similarly suggest that impaired tight junction integrity plays an important role in the pathogenesis of cholangiopathies (1) (2) (3) . Most in vitro research on biliary physiology and pathology, however, employs cells either cultured in 2D monolayers or as organoids in 3D extracellular matrix (ECM). These conventional methods fail to replicate many key aspects of bile duct structural organization or to recapitulate important tissue-level integrated physiological functions such as forming a protective barrier and compartmentalizing bile.
Microfluidic organs-on-chips can overcome some of these limitations (4) . Soft lithography, which is used to design organs-on-chips, allows control of surface features over a range of physiologically-relevant scales. Organs-on-chips can mimic aspects of the physiology of cell-cell and cell-ECM junctions in tissues including the alveolar-capillary interface (5) , the blood-brain barrier (6) (7) (8) , and liver sinusoids, in a controllable way, allowing both highresolution imaging and biochemical and metabolic analyses in real time. The technology has great potential to advance the study of tissue development, physiology and pathophysiology.
To capture the structure and environment of the bile ducts, we used organ-on-chip technology to develop a microengineered bile duct with controllable architecture and surrounding matrix. We demonstrate that a self-organized cholangiocyte-lined channel faithfully recapitulates key functions of the bile duct and enables us to study the barrier function of cholangiocytes monolayer quantitatively and independently from either the apical or basolateral side. As a proof-of-concept, we use this model to demonstrate the protective role of the cholangiocyte apical glycocalyx.
Materials and Methods

CELL ISOLATION AND CULTURE
The small cholangiocyte cell line was originally isolated from normal mice (BALB/c) and immortalized by transfection with the SV40 large-T antigen (9) . Primary cholangiocytes were isolated from extrahepatic bile ducts (EHBD) of normal adult mice (BALB/c) as described previously (10) . Cells were cultured in low glucose Dulbecco's Modified Eagle Medium (DMEM; Thermo Fisher Scientific, Waltham, MA) supplemented as previously reported (9) (10) (11) .
FABRICATION OF THE BILE DUCT-ON-A-CHIP
Microfluidic devices were fabricated using soft lithography as described previously (12, 13) (Fig. 1A) . Polydimethylsiloxane (PDMS, Sylgard 184, Dow-Corning, Midland, MI) devices were treated with 0.01% (v/v) poly-L-lysine for 1 h and 0.5% (v/v) glutaraldehyde for 20 min to promote collagen adhesion. After the devices were washed overnight in water and for 30 min in 70% ethanol, steel acupuncture needles (160 μ m diameter, Seirin, Kyoto, Japan) were inserted and the devices were then sterilized under UV for 20 min. A solution of 2.5 mg/ml rat tail type 1 collagen (Thermo Fisher Scientific), 1X DMEM medium, 10 mM HEPES, 0.1 M NaOH and NaHCO 3 (0.035% w/v) was infused via the side ports and allowed to polymerize for 20 min at 37°C.
Needles were removed to form channels, which were then coated with 100 μ g/ml laminin overnight (via the large reservoir ports) at 37°C. A suspension of 0.5 million/ml cholangiocytes was introduced into the reservoir ports. Cells were allowed to adhere to the top surface of the channel for 2 min; devices were then flipped to allow cells to adhere to the bottom surface of the channel for 5 min. Non-adherent cells were removed by rinsing with cell culture medium and the devices were filled with fresh medium. Devices were maintained at 37°C (5% CO 2 ) for 7 d on a rocker at 5 rpm with daily medium changes until the development of compact monolayers.
PERMEABILITY MEASUREMENTS
To magnification. The diffusive permeability coefficient (Pd) was calculated by measuring the flux of dextran into the collagen gel and fitting the resulting diffusion profiles to a dynamic mass conservation equation, as described previously (12, 14) .
IMMUNOSTAINING AND LECTIN STAINING
Cholangiocyte monolayers in the device were fixed with 4% Paraformaldehyde (PFA) at 
STATISTICAL ANALYSIS
Statistical significance was assessed using one-way ANOVA. p<0.05 was regarded as statistically significant and calculated with Prism 7 (GraphPad Software, La Jolla, CA).
All data are presented as mean ± standard deviation (SD). Sample size is indicated in the corresponding figure legends.
Results
FABRICATION OF THE BILE DUCT-ON-A-CHIP
In order to study the function of the apical and basal sides of cholangiocytes independently, we developed a microfluidic device consisting of a PDMS support with a 160 μm cholangiocyte-lined channel through a matrix bulk; apical and basal sides of the channel were accessible through separate ports ( Figure 1A , B). The device was designed as per previously-described models of endothelium-lined, vascular-mimetic channels (12, 13) . To generate a bile duct-on-a-chip, the channel was formed within a collagen plug and the lumen was coated with laminin (100 To determine whether the bile duct-on-a-chip recapitulated the barrier function of the bile duct, we perfused the lumen with FITC-dextran ranging in size from 4 to 70 kDa.
There was no obvious leakage of fluorescent dextran into the collagen matrix even after 10 minutes ( Figure 1E ). Quantification of permeability showed an increase as the molecular weight of the dextran decreased ( Figure 1F ). The measured permeability of cholangiocyte cell line was comparable with that measured in rat ex vivo systems using insulin (5.8 kDa; 0.45 μ m/s) (15) . This model of the bile duct thus mimics the barrier function of ducts in vivo.
1 0
CHARACTERIZATION OF THE BILE DUCT-ON-A-CHIP
We used immunofluorescence staining to characterize the cholangiocytes in the channel. F-actin staining showed that cholangiocytes grew into a compact monolayer, 
A SUPERCONFLUENT MONOLAYER IS REQUIRED FOR OPTIMAL BARRIER FUNCTION
Full barrier function required that cholangiocytes were not just confluent but "superconfluent" and compact ( Figure 3A) ; as the cholangiocyte monolayer grew more dense, permeability decreased significantly ( Figure 3B ). By F-actin staining, we confirmed that the permeability difference between what we term a confluent versus a compact monolayer was not the result of gaps in the monolayer ( Figure 3C ). Cell height increased more than two-fold in the compact compared to the confluent monolayer ( Figure 3D ). To determine the cell density of cholangiocyte monolayers in vivo, we counted cell number as a function of monolayer length in adult mouse EHBD and in confluent and compact devices ( Figure 3E ). We found that compact monolayers were more dense than confluent ones, and that mice EHBD ( Figure 3E , F) had an even higher cell density. These results suggested that the biliary epithelium forms a dense, compact monolayer -beyond confluence -in order to form a mature barrier.
THE APICAL AND BASAL SURFACES OF THE MONOLAYER CAN BE ACCESSED INDEPENDENTLY
In order to determine whether the apical and basal surfaces of cholangiocytes in the device could be accessed independently, we applied FITC-dextran through either the large reservoir ports, which are directly connected to the lumen, or the small side ports, which connect to the basal surface of the monolayer through the collagen bulk. We found that FITC-dextran added through the reservoir ports remained within the lumen ( Figure 4A Biliatresone is a plant isoflavonoid that is toxic to cholangiocytes and causes a syndrome mimicking the pediatric disease biliary atresia in neonatal livestock and larval zebrafish (16) . We previously demonstrated that biliatresone applied to the basal surface of a cholangiocyte spheroid causes mislocalization of the apical markers ZO-1 and Ecadherin and increases cholangiocyte monolayer permeability (11) . A limitation of these spheroid studies was that biliatresone could only be added to the basal surface. As a demonstration of the potential use of the bile duct-on-a-chip device, we showed that biliatresone treatment caused cholangiocyte damage, as evidenced by increased permeability of monolayers in the device, and that this damage was worse with basal as opposed to apical administration ( Figure 4E ).
Cholangiocytes are adapted to tolerate exposure to toxic bile at their apical surfaces though it has been difficult to study in cell culture. Impaired duct barrier function may lead to bile leakage through the monolayer, and cause damage from the basolateral side, which is less tolerant of bile (17) (18) (19) . As a second illustration of the potential use of the bile duct-on-a-chip device, we exposed cholangiocytes to 1 mM of the bile acid glycochenodeoxycholic acid (GCDC) from either the apical or basal side. GCDC treatment caused significantly more damage, as defined by increased permeability, when applied to the basal side rather than the apical side ( Figure 4F ), suggesting that once bile leaks through the epithelial monolayer, it can cause additional damage through the basolateral side of the barrier, leading to a feedback loop of further damage and increased leakage.
THE GLYCOCALYX PROTECTS CHOLANGIOCYTES FROM BILE ACID-INDUCED DAMAGE
Cholangiocytes have an apical glycocalyx that protects them from bile acid toxicity (20, 21) .
We stained the apical surfaces of the cholangiocyte monolayer in the bile duct-on-a-chip using the lectin Sambucus nigra agglutinin (SNA), which binds to α 2-6 -bound (terminal)
sialic acid residues, and demonstrated that the sialic acid-enriched glycocalyx was maintained in cholangiocytes in the device and was appropriately localized to the apical surface ( Figure 5A ). We also stained cells in the channel with the lectin soybean agglutinin (SBA), which only detects carbohydrates lacking terminal sialic acid residues ( Figure 5E ), confirming a lack of cholangiocyte staining at baseline ( Figure 5B ). We then treated cells with neuraminidase, applied apically, to remove the terminal sialic acid.
Post-treatment staining with SNA was minimal, while there was new staining with SBA, confirming the presence of apical sialic acid residues in untreated cells and the efficacy of neuraminidase in this system ( Figure 5C, D) . To test the role of the glycocalyx in protecting cholangiocytes from bile acids, we perfused the device lumen with GCDC (1 mM) before or after treatment with neuraminidase, and then measured monolayer permeability. We found no effect of GCDC, with or without neuraminidase treatment, on permeability to 70 kDa FITC-dextran; however, GCDC alone increased the permeability to 4 kDa FITC-dextran, and GCDC exposure of neuraminidase-treated cholangiocytes increased permeability to both 4 kDa and 10 kDa FITC-dextran ( Figure 5F ). Taken
together, these findings demonstrate that the cholangiocyte-lined channel is resistant to bile acid toxicity and that the glycocalyx plays a protective role.
CONSTRUCTION OF A BILE DUCT-ON-A-CHIP WITH PRIMARY MURINE EXTRAHEPATIC CHOLANGIOCYTES
To demonstrate that the bile duct-on-a-chip can be used with cells from various sources, we also used primary murine extrahepatic cholangiocytes ( Figure S1A ). Primary confirmed that primary cholangiocytes in the bile duct-on-a-chip were ciliated and highly polarized. In permeability assays, there was no visible leakage of 4kDa FITC-dextran from the lumen even after 10 mins ( Figure S1B , Movie S1). Analysis of the intensity change along a line perpendicular to the channel showed almost no increase in intensity across the gel after 2 mins ( Figure S1D ), in contrast to the cholangiocyte cell line ( Figure S1C ) and the permeability to 4 kDa FITC-dextran of primary cholangiocyte was about only 16% of that for the cholangiocyte cell line ( Figure S1E) . Thus, the primary cell-lined device demonstrated even better barrier function than the device lined with the cholangiocyte cell line ( Figure S1E ).
Discussion
We have developed an in vitro model of the bile duct by employing organ-on-chip technology, recapitulating not only the three-dimensional architecture of the bile duct but also its barrier function. We demonstrated that cholangiocytes are polarized in the device and that permeability is comparable to in vivo values for the bile duct, requires a dense monolayer, and can be quantified. We also showed that the device enables apical vs. basolateral treatments and that cells respond differently depending on the side of exposure. As a demonstration of the potential use of the device in studying biliary physiology, we showed that the apical glycocalyx plays a protective role against bile acid toxicity and that the biliary toxin biliatresone has greater toxicity when applied to the basal surface. The bile duct-on-a-chip thus represents a novel in vitro model for However, the cholangiocytes cultured on the fiber have outward-facing apical surfaces, in contrast to ducts in vivo and the bile duct-on-a-chip.
Previous studies have suggested that epithelial cell confluence is associated with morphology, polarity and barrier function (22) (23) (24) (25) . Although changes in transepithelial electronic resistance have been reported to be minimal after cells reach confluence (24) , we found that permeability decreased significantly when cells progressed from confluent to compact, with associated changes in height, suggesting changes in tight junction molecules (25) . These results demonstrate that compactness is required for an optimal barrier function, and suggest that confluence may be an intermediate rather than
ultimate goal in the repair of an injured epithelial layer.
We demonstrated that this device can be constructed with primary murine extrahepatic cholangiocytes and that in the device these cells stably expressed biliary markers, junctional molecules and bile salt transport proteins and also developed cilia on their apical surfaces, facing the lumen. The bile duct-on-a-chip thus offers the opportunity to carry out experiments using genetically-modified cholangiocytes and to compare intravs. extra-hepatic cholangiocytes. Human cholangiocytes, including those derived from induced pluripotent stem cells, could also be studied using this device.
In conclusion, our bile duct-on-a-chip mimics the basic features of the bile duct, making it a novel platform for in vitro studies of biliary physiopathology.
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